脂质体布比卡因用于周围神经阻滞术后镇痛：比较对象决定临床结论的证据整合

Liposomal Bupivacaine for Postoperative Analgesia Following Peripheral Nerve Block: An Evidence Synthesis in Which the Comparator Determines the Clinical Conclusion

摘要: 脂质体布比卡因(liposomal bupivacaine, LB)旨在以单次给药延长术后镇痛，但其在不同术式和不同研究中的疗效结论并不一致。造成这种差异的关键不只是药物本身，而是比较对象、阻滞平面、基础多模式镇痛方案和结局定义不同。本文基于围绕该问题定向收集的制剂学研究、随机对照试验、系统评价、安全性资料和镇痛结局方法学文献，采用叙述性整合方法，围绕“LB相对何种方案、用于何种手术、能否产生临床上值得的增量净获益”进行综述。现有证据表明：LB相对安慰剂具有明确镇痛活性；但相对普通局麻药、普通局麻药联合地塞米松或连续导管等临床相关主动对照时，增量获益不稳定。足踝手术腘窝坐骨神经阻滞，尤其拇囊炎切除术，是目前疼痛与阿片消耗同步改善证据较有说服力的场景；肩部手术存在效应信号，但结果高度依赖对照方案，且需重视膈神经和肺功能影响；全膝关节置换关节周围浸润及心脏外科特定胸骨旁平面研究不支持常规应用。LB的临床定位不应建立在预设“长效”时程上，而应以疼痛–阿片整合结局、恢复质量、呼吸和运动安全性、导管管理负担及成本共同判断。建议将LB作为多模式镇痛中的选择性工具，而非所有周围神经阻滞的常规替代方案。

Abstract: Liposomal bupivacaine (LB) is intended to prolong postoperative analgesia with a single injection, yet its efficacy conclusions are inconsistent across procedures and studies. The key to this inconsistency lies not only in the formulation itself, but also in differences in comparators, block sites, background multimodal analgesia regimens, and outcome definitions. Based on formulation studies, randomized controlled trials, systematic reviews, safety data, and analgesic-outcome methodology literature purposively collected around this question, this narrative synthesis addresses the following question: relative to which regimen, in which procedure, can LB yield a clinically worthwhile incremental net benefit? Current evidence indicates that LB has definite analgesic activity versus placebo; however, its incremental benefit is inconsistent when compared with clinically relevant active controls such as plain local anesthetics, local anesthetics plus dexamethasone, or continuous catheters. Popliteal sciatic nerve block for foot and ankle surgery, particularly bunionectomy, currently provides the most persuasive evidence of concurrent improvement in pain and opioid consumption. In shoulder surgery, effect signals exist, but the results depend strongly on the comparator, and phrenic nerve and pulmonary effects must be taken seriously. Studies of periarticular infiltration in total knee arthroplasty and of a specific parasternal plane block in cardiac surgery do not support routine use. The clinical positioning of LB should not be built on a presumed “long-acting” duration, but should be judged jointly by integrated pain-opioid outcomes, quality of recovery, respiratory and motor safety, catheter management burden, and cost. We recommend positioning LB as a selective tool within multimodal analgesia rather than a routine replacement for all peripheral nerve blocks.